Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap
This article was originally published in The Gray Sheet
Executive Summary
Chugai's decision to spin off its wholly-owned diagnostic subsidiary Gen-Probe following a merger with Roche's Japanese unit, Nippon Roche, will preserve worldwide competition between Roche's Cobas AmpliScreen nucleic acid test (NAT) line and Chiron's Procleix NAT, developed with Gen-Probe
You may also be interested in...
Chiron/Gen-Probe Procleix HIV/HCV NAT Test To Cost $10-15 Per Screen
FDA is preparing to release a draft guidance on nucleic acid test (NAT) screening of whole blood samples following approval of Chiron and Gen-Probe's Procleix HIV-1/HCV NAT assay on Feb. 28
Chiron/Gen-Probe Procleix HIV/HCV NAT Test To Cost $10-15 Per Screen
FDA is preparing to release a draft guidance on nucleic acid test (NAT) screening of whole blood samples following approval of Chiron and Gen-Probe's Procleix HIV-1/HCV NAT assay on Feb. 28
DOBI Aims To Be $100 Mil. Firm Within A Year Of ComfortScan Launch
DOBI Medical Systems hopes to gain FDA approval in the third quarter of 2002 for its ComfortScan dynamic breast imaging system based on an ongoing, 10-center, 1,200 patient U.S. pivotal trial of the system for use as an adjunct to mammography